FDA approves new macular degeneration treatment

Share this article:

The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision loss in the elderly.

Eylea, which is manufactured by Regeneron Pharmaceuticals, is a slightly less expensive treatment, costing $1,850 per injection, versus $1,950 for Genentech's Lucentis.

Both Lucentis and Eylea are still more expensive than the cancer drug Avastin, also made by Genentech. Avastin, which was recently pulled by the FDA as a breast cancer treatment option, is used as an off-label drug to treat macular degeneration, and accounts for over half of that market, The New York Times reports. Avastin costs only $50 per dose, but has been hampered recently due to reports that tainted vials of the drug infected users with Streptococcus endophthalmitis.

 

Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.